We clinch all Intellectual Property and capitals from our pipeline projects,
while we clinch new licensing and investment agreements to advance our innovative myosin inhibitor portfolio.
Clinch Biosciences team deeply characterizes
motor enzymes
which are responsible for essential cellular movements providing the basis of life. Through modulation of these enzymes, we
improve quality of life
of patients suffering from severe musculoskeletal and cardiovascular diseases and metastasis forming cancers.
Clinch Biosciences will revolutionize preclinical drug discovery by applying its
one-lab strategy
which means that all members of the team from
chemistry-to-clinics
stay in close contact and mutually accelerate each other’s work by continuous feedback and open communication.
We believe that
real values
evolve from
solid basic research
through understanding the fundamental chemical and biological processes behind the mechanism of action of drugs.
Once a project with a potential business value emerges, we plan to establish
a separately funded but jointly managed entity we call a
to accelerate clinical development.
